|Assessment process complete
|For the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed on or after docetaxel therapy.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Evaluation Recommended
|Full submission received from Applicant
|NCPE assessment completed
|NCPE assessment outcome
|Reimbursement not Recommended
In October 2013, Astellas Pharma Co Ltd submitted an economic evaluation on the cost effectiveness of enzalutamide for this indication. An updated dossier was submitted on the 6th December 2013.
The NCPE believe that, at the submitted price, enzalutamide is not cost effective for the treatment of adults with metastatic castration-resistant cancer whose disease has progressed on or after docetaxel.
The HSE has approved reimbursement following confidential price negotiations.